Provided By GlobeNewswire
Last update: Sep 6, 2023
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.
Read more at globenewswire.comNASDAQ:GNTA (8/12/2025, 10:58:29 AM)
3.51
+0.02 (+0.57%)
Find more stocks in the Stock Screener